According to a research report “Plasma Fractionation Market is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as increased application of immunoglobulins for treatment of various therapeutic areas such as hematology, neurology and pulmonology, and the use of protease inhibitors for the treatment of lung diseases and hepatic diseases that have growing incidence rate. However, the increased cost of plasma products, limited reimbursements, and the growth of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

Download Report Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284

The growing use of immunoglobulins in various off-label indication and growing genetic research for characterizing and diagnosing immunodeficiency resulting in increased application of plasma fractionation products, growing geriatric population such as the population of people above 60 age expected to reach 2.1 billion by 2050, increased use of protease inhibitors such as alpha-1-antitrypsin for the treatment of lung diseases, and increased incidence of communicable diseases are the major factors driving the growth of this market.

Key Market Player:

The global plasma fractionation market is highly consolidated. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India). Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.

Driver: Growing use of immunoglobulins for various therapeutic area

The increasing use of immunoglobulins for various therapeutic areas, such as autoimmune diseases, immune deficiencies, and infectious diseases, is driving the growth of the plasma fractionation market. Immunoglobulins are proteins produced by the immune system to fight against infections, allergies, and other diseases. Plasma fractionation processes are used to extract immunoglobulins from the plasma of healthy donors. These immunoglobulins are then used to treat various diseases, such as primary immunodeficiencies, autoimmune diseases, and infectious diseases. In addition, the increasing demand for immunoglobulins in the research sector is also driving the growth of the plasma fractionation market.

Restraint: Use of recombinant alternatives for certain plasma products

The use of recombinant alternatives for certain plasma products such as factor VIII, IX and von Willebrand factor is a key restraint for the growth of the plasma fractionation market. The advent of recombinant alternative products has enabled more efficient and cost-effective treatment of hemophilia, while also eliminating the risk of infections associated with the use of plasma-derived products. Numerous companies, such as Novo Nordisk, have launched recombinant alternative products in the market, which has significantly impacted the market of plasma-derived products.

Opportunity: Increased risk of communicable disease

The increasing risk of communicable diseases such as influenza, coronavirus, and HIV is expected to drive demand for plasma fractionation products. According to the World Health Organization (WHO), the number of reported cases of communicable diseases such as HIV, malaria, and tuberculosis has been increasing consistently over the past few decades. This has necessitated the need for more efficient and effective treatments and therapies for these diseases, which is expected to drive the demand for plasma fractionation products in the coming years.

This research report categorizes the plasma fractionation market to forecast revenue and analyse trends in each of the following submarkets:

By Product

• Immunoglobulins
• Coagulation Factor Concentrates
• Albumin
• Protease Inhibitors
• Other Products

By Application

• Neurology
• Immunology
• Hematology
• Critical care
• Pulmonology
• Hemato-oncology
• Rheumatology
• Other Applications

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284

The pulmonology segment is expected to grow at the highest CAGR during the forecast period

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely significantly increased use of protease inhibitors, such as alpha-1-antitrypsin in recent years. Also, with the rising geriatric population, the prevalence of AATD and COPD is expected to increase across the globe. With the rising incidence of target diseases, the demand for plasma-derived alpha-1-antitrypsin is expected to increase in the coming years making the pulmonogly segment the fastest growing during the forecast period.

North America was the largest regional market for plasma fractionation market in 2021

The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the innovations in manufacturing processes such as presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA, high number of registered hemophilic patients and largest number of plasma collection center. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in increasing number of hemophilic patients, as well as factors such as the increasing number of organ transplantations, modified regulations and monitoring of the implementation of procedures, policies, and guidelines to promote innovation and commercialization, increasing awareness about technologically advanced products in the region, and the improving standard of living across several APAC countries.

Report Link: Plasma Fractionation Market

Table of Content:

1 INTRODUCTION (Page No. – 45)

• OBJECTIVES OF THE STUDY
• MARKET DEFINITION
• MARKET SCOPE
• CURRENCY
• LIMITATIONS

• RESEARCH METHODOLOGY (Page No. – 49)
  • RESEARCH DATA
  • MARKET ESTIMATION METHODOLOGY
  • MARKET GROWTH RATE PROJECTIONS
• EXECUTIVE SUMMARY (Page No. – 60)

FIGURE 10 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)

FIGURE 11 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)

FIGURE 12 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)

FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

• PREMIUM INSIGHTS (Page No. – 63)
  • PLASMA FRACTIONATION MARKET OVERVIEW
  • NORTH AMERICA: MARKET, BY PRODUCT & COUNTRY (2021)
  • GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• MARKET OVERVIEW (Page No. – 66)
  • INTRODUCTION
  • MARKET DYNAMICS
  • IMPACT ASSESSMENT OF GLOBAL MARKET
  • PRICING ANALYSIS
• PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. – 100)
  • INTRODUCTION
  • IMMUNOGLOBULINS
  • COAGULATION FACTOR CONCENTRATES

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.